Treat-to-target With Secukinumab in Axial Spondyloarthritis

Summary

A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.

Timeline

Start

2019-01-15

Primary completion

2021-02

Completion

2021-02

Outcome

Missed primary endpoint

paper The primary end point occurred in 14 (52%) of week 16 remitters versus 19 (41%) of week 16 non-remitters (p=0.53). PMID 41963078 ↗

Publications

• Vladimirova N, Ostergaard M, Seven S, Moller JM, Jensen B, Ostgard R, Poggenborg R, Madsen OR, Hendricks O, Brix L, Georgiadis S, Pedersen SJ. Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE). RMD Open. 2026 Apr 10;12(2):e006774. doi: 10.1136/rmdopen-2026-006774.

Drugs

Indications